Company presentation - Mondobiotech

Business validation
Science
IP
Business
Strategic Alliances
Financial
Founders
More than 300 potentially efficacious treatments discovered.
1 product in phase III and 4 products in phase II clinical trials,
6 products ready to enter in clinical trials phases, 32 products to start
clinical development, 260 products to start development.
6 Orphan Medicinal Products Designations in USA and Europe, 1 patent
granted for IFN-γ (EP 0 795 332 B1) and the products in the pipeline
protected by patent applications.
10 indications licensed to two partners, InterMune and Lung Rx, a United
Therapeutics subsidiary (incl. Biogen Idec), and capacity to license more.
23andMe for genetic research for patients in rare diseases;
Bachem for peptides manufacturing; Nebu-Tec for inhalation;
SRI for preclinical testing and biological screening.
Traded at the SIX Swiss Exchange with symbol RARE,
top investors from family firms continue their commitment
to the company, BSI bank of Generali Insurance Group
as house bank and WR Hambrecht bank as financial advisor.
Majority shareholders still involved as from the beginning with the same
long term investment vision.
20/33